Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6537
    +0.0014 (+0.21%)
     

  • OIL

    84.44
    +0.87 (+1.04%)
     

  • GOLD

    2,355.40
    +12.90 (+0.55%)
     

  • Bitcoin AUD

    98,449.09
    +510.70 (+0.52%)
     

  • CMC Crypto 200

    1,387.65
    -8.88 (-0.64%)
     

  • AUD/EUR

    0.6096
    +0.0023 (+0.37%)
     

  • AUD/NZD

    1.0987
    +0.0030 (+0.27%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,115.78
    +36.92 (+0.46%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,047.16
    +129.88 (+0.72%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Merck says study shows COVID-19 drug causes quick reduction in virus

Reuters
·1-min read

March 6 (Reuters) - U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19.

"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.

The antiviral is being currently tested in a Phase 2/3 trial that is set to be completed in May.

Merck decided to focus on therapeutics after its two COVID-19 vaccines failed to generate desired immune responses, prompting it to abandon the program in January.

(Reporting by Ann Maria Shibu in Bengaluru; Editing by Christian Schmollinger)